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Endurance exercise can induce muscle fiber type change from type II glycolytic to 
oxidative type I muscle fibers. The exact molecular mechanism is still not clear, but the 
nuclear receptor PPAR-* (peroxisome proliferator-activated receptor delta) and co-
activator, perxisome-proliferator-activated receptor-gama co-activator-1" (PGC-1") are 
the key factors responsible for increased mitochondrial biogenesis and increased 
oxidative capacity of muscle fibers, determining in this way the muscle phenotype. The 
paper explores the possible mechanisms of regulation and the role of PPAR-* in the 
skeletal muscle and muscle fiber type determination in order to find solutions for 
complex physiological properties, such as fatigue and endurance. Acta Medica Medianae 
2011;50(2):57-62. 
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Introduction 
 
  Morphologically, histochemically and functio-
nally, skeletal muscle fibers can be classified as: 
type I (slow or oxidative) and type II (glycolytic 
or fast) muscle fibers. There are significant 
differences among them in relation to the 
contraction, metabolism and fatigue. 
  Type I (slow or red muscle fibers) contains 
a lot of red pigment (myoglobin and  mito-
hondrial cytochromes), so the muscles are dark 
red colored. They contract slower than the white 
fibers, but are capable of prolonged and strong 
contractions. These fibers mainly use oxidative 
metabolism for energy production and contain 
many mitochondria. Muscle action potential is 
about 100 milliseconds, which is enough for 
glucose and fatty acids to efficiently metabolize. 
Muscles are stable and long-term supply of 
energy from ATP, and therefore, type-I fibers are 
known as the “endurance muscle”. 
  Type II (fast or white fibers) contains little 
less myoglobin and mitochondria, and therefore 
less cytoplasm. Energy for their work comes from 
anaerobic glycolysis. Triggering the action 
potential is less than 10 milliseconds and fast 
contractions are  supported by an endoplasmic 
reticulum, so that they can quickly release and 
reabsorb by calcium ions (about ten times faster 
than oxidative fibers). During strong contractions 
they tire easily. Glycolytic metabolism leads to 
rapid production of lactic acid, so that the 
muscles need rest and recovery in order to 
remove lactic acid and have oxygen levels 
restored (1,2). 
  Genetic factors are often the reason for the 
variation in the distribution of fiber types; however, 
physical activity is frequently emphasized. Adult 
skeletal muscles are characterized by plasticity and 
may be subjected to conversion into different 
types of fibers in response to exercise or 
modulation of motoneural activities (3-6). A high 
percentage of nuclear receptor PPAR-* in 
oxidative muscle fibers (10-50 times higher than 
the other isoforms) has pointed to its possible 
role in the formation of these fibers. For the 
regulation and activation of PPAR-*, cofactors 
and ligands are required to express transcrip-
tional activity (7-9). 
 
Role of PPAR-* in skeletal muscle 
 
  Skeletal muscles constitute about 50% of 
total body mass, so their metabolism is an 
important part of the overall metabolism of the 
whole organism. As they belong to plastic 
tissues, skeletal muscles adapt in response to 
exercise, and these local signals and molecular 
regulation are very important for their phenotype.   
  PPARs are nuclear protein receptors that 
act as transcription factors in the regulation of 
gene expression in the adipose tissue, heart, 
muscle, placenta, etc. This family of transcription 
factors in man contains 48 members, which differ 
structurally and functionally (10). There are three 
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different  isoforms:  ",  β/* and (. PPAR-* is an 
important metabolic sensor and regulates 
transcription by heterodimerizing with retinoid X 
receptor. The  receptor complex binds to PPAR 
element located in the regulatory region of genes 
and binds to DNA in the absence of ligands. 
Ligand binding leads to induction of gene 
expression. Bonding is possible due to cavitation, 
and ligand specificity is determined by 
complementarity between the cavity and  ligand 
(11). Ligands that activate PPAR-* are saturated 
or unsaturated long chain fatty acids (12). 
Endogenous substances that can activate PPAR-*, 
in addition to fatty acids, are triglycerides, 
leukotrienes, eicosanoids, prostaglandins, vitamin 
A metabolic retinoic acid and a large number of 
synthetic ligands (13,14). 
  Animal studies have shown that PPAR-* 
plays an important role in metabolic adaptation 
of many tissues to changes in external 
conditions, and are involved in the regulation of 
fatty acid metabolism of the skeletal muscle and 
adipose tissue through the expression of genes 
involved in the takeover of fatty acid ß-oxidation, 
mitochondrial respiration, generate energy, thermo-
genesis (15-18). This isoform in comparison to other 
PPARs is most common in the skeletal muscle 
(19) and has the highest expression in the 
oxidative type I muscle fibers compared to 
glycolytic type II muscle fibers (18). 
  It is believed that a large number of 
physiologic and pathologic factors affect the 
content of PPAR-* in skeletal muscle. Literature 
data have shown that both short and endurance 
training increase the expression of PPAR-delta, 
both in human and in animal studies (20,21). 
Endurance training within three weeks of 
swimming in the animal model led to increased 
expression of PPAR* in the skeletal muscle, and 
such an increase was obtained after a single 
exhaustive bout of cycling in humans (22). 
Mazzatti et al.(23) showed that a short-term 
disuse of hind-limb led to increased PPAR-* 
mRNA, and this marked increased expression 
represents an adaptive, stress-induced response 
in the prevention of major metabolic consequences. 
Thus, in patients with long-standing spinal cord 
injuries, the contents of this nuclear receptor 
decreased in the skeletal muscle (24). 
  Data on the impact of nutrition factors on 
the expression of PPAR-* are controversial, but 
the general conclusion is that starvation leads to 
rapid but transient increase in the expression of 
PPAR-delta in the skeletal muscle (25,26), 
suggesting its important role in the metabolism 
of fatty acids. However, the exercise itself and 
muscle contractions have proved to be important 
regulators of the contents of the PPAR-* in the 
skeletal muscle. This conclusion was induced by 
suppression of free fatty acids (using nicotinic 
acid as antilipolytic drug) with the increased 
mRNA expression of PPAR-* in the skeletal 
muscle (27). Further research on the effects of 
different long chain fatty acids in cell culture 
showed no significant effect on the expression of 
PPAR-*, what has led to the conclusion that the 
effect of fatty acids is an important regulator of 
expression. However, the nature of this regulation 
not been clarified yet, so that the emphasis is on 
the presence of activating ligands and some 
transporters of fatty acids (28). 
  
  Role of PPAR-* in determination of 
muscle fiber type 
 
  Molecular mechanism responsible for 
regulating the muscle fiber type has not been 
defined yet. In order to prove that the PPAR-
delta is responsible for the regulation and 
development of oxidative type I muscle fibers, a 
group of scientists has made transgenic mice 
(TG) by inserting the zygote with the viral 
transcription activator, VP16, combined with 
PPAR-* gene (18). This has increased the 
transcription of PPAR-* responsive genes and 
created a modified transcriptional regulation 
specification and growth of muscle fibers. Biopsy 
tissue samples were compared with normal 
tissues of mice and showed the increased 
expression of PPAR-* protein. Mitochondrial DNA 
was increased more than twice in skeletal 
muscles and muscle fibers possessed the 
markers of oxidative muscle. The whole 
physiology of the physical abilities of the mutant 
mouse was much more advanced than the 
normal type of mice, including the postponement 
of fatigue and better physical performances. 
These progressive changes in oxidative capacity 
and, consequently, the changes in the type of 
muscle fibers, led to a significant improvement in 
the profile of exercise, not just a result of higher 
expression of PPAR-*. In a recent report by 
Luquet et al. (29), a simple activation of PPAR-* 
expression in muscle was not enough to change 
the type of fiber, although the oxidative enzymes 
were increased. This fact proves that both   
activation signals and ligands are necessary and 
important. Possible regulatory role of PPAR-* in 
determining the type of muscle fiber is perhaps 
the increased expression of his coactivators or 
reduction of his corepressors (30). Increased 
expression of PPAR-* has also lead to increased 
expression of genes involved in fatty acid 
catabolism. All these results obtained in 
experiments with transgenic animals are the 
result of altered expression of mRNA during 
active muscle development.  Whether these 
processes are present in the regulation of muscle 
fiber types in adult and mature muscle as well is 
not entirely clear. Such data related to humans 
are very scarce (31,32), which points to the 
necessary caution in comparing data in animals 
and man. However, even in the skeletal muscle 
in humans, a higher expression of PPAR-* and 
PGC1-" has been recorded in individuals with 
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example, in elite cyclists) as well as their 
significantly reduced expression in people with 
spinal cord injuries, in which type I fibers have 
been selectively lost (23). With the change of 
muscle fiber types, PPAR-* also leads to increased 
muscle vascularization (33-35). 
  These experiments favor the hypothesis 
that PPAR-* plays an important role in the 
adaptive response of skeletal muscle to endurance 
exercise. Increased expression of PPAR-* was 
observed after several weeks of exercise in the 
animal model, and similar changes were found in 
human muscle (26). What the molecular mecha-
nisms that lead to increased expression of PPAR-
* in skeletal muscle during endurance training 
are remains unclear. Also, the relationship 
between the levels of expression and activation 
PPAR-* and the proliferation of myoblasts and 
formation of certain types of muscle fiberson is not 
quite clear. Possible responses include the creations 
or increasing of ligand number for PPAR-* under 
the influence of exercise, where the burning of 
fatty acids in the tissues, together with their 
metabolites, can affect the activation of PPAR-*. 
According to another model, exercise can induce 
the expression of PGC-1" (gamma co-activator 
1alfa), which then activates PPAR-* (which is 
otherwise happening in the experiments, even in 
the absence of ligand) (36-38). This coactivator 
is present in tissues with higher metabolic 
activity, liver, brain, heart, adipose tissue and 
skeletal muscle (39,40) which are characterized 
by a large number of mitochondria, because of 
high energy demands. It has been noted that 
muscles during exercise increase mitochondrial 
content, enhance the expression of mitochondrial 
genes (cytochrome oxidase) and myoglobin and 
are resistant to fatigue (41), demonstrating the 
important role of PGC-1" for the metabolic 
changes in the muscle (42). Its experimentally 
increased expression also showed a protective 
effect of the changes associated with atrophy 
(43). Mechanisms by which PGC-1" induced 
changes in the muscle appeared to involve calcium 
calmodulin-dependent protein kinase (44), activation 
of calcineurin and activation of transcription factors 
(45,46). The ctivation of this signaling pathway 
leads to increased transcription of genes expressed 
in oxidative fibers and results in enhanced 
mitochondrial biogenesis (47-49). A detailed study 
of Lin et al. on the animal model (8) marks this 
coactivator as an important physiological regulator 
for type-I fibre specification, but also points to the 
fact that PGC-1 " does not completely convert all 
the fibers, including thus other signals which can 
determine a muscle fibre phenotype.  
  Muscle remodeling that occurs by the 
activation of this nuclear receptor may be 
associated also with endocrine function of the 
skeletal muscle. Physical exercise that increases 
the burning of fatty acids, also changes the level 
of muscle cytokine secretion, which are denoted 
as myokines in controlling metabolic responses of 
other tissues, especially adipose tissue (50). 
Important metabolic link between the skeletal 
muscle and adipose tissue is reflected in the total 
body mass, insulin sensitivity and metabolism of 
fatty acids. This link is not a unidirectional flow of 
messengers from the “endocrine” adipose tissue 
to a rather “passive” muscle (as previously 
explained their relationship); moreover, these 
skeletal muscles are considered another endocrine 
tissue able to express a large number of 
molecules with endocrine actions. Right here is 
the place PPAR-*, which connects the functions of 
these tissues and in some, yet unexplained 
manner, maintains the metabolic balance (51). 
The correlation between interleukin IL-6 and 
PPAR-* is also interesting, because exercise 
induces both an increase in PPAR-* expression 
and increase in IL-6 release (52). The interleukin-6 
favors fatty acid oxidation in skeletal muscle 
during exercise, so there is a hypothesis (53) 
about a role of IL-6 during endurance exercise in 
changing muscle fiber composition towards a 
more oxidative, more insulin-sensitive muscle 
fiber, although the molecular basis is unclear.  
  
  Conclusion 
 
  There is strong evidence that PPAR-* is one 
of the key regulators in determining the type-I 
oxidative muscle fibers in skeletal muscles, which 
are determinants of endurance and speed, 
although the exact molecular mechanism is still 
unknown. Possible mechanisms include exercise-
induced burning of fatty acids, or induce 
coactivator PGC-1-", which both increase the 
expression of PPAR-*, and activates the mito-
chondrial biogenesis and oxidative metabolism, 
which affects the phenotype of the muscle fibers. 
The fact that  various pharmacological activators 
and ligands may induce the increased expression 
of PPAR-* and enhance physical performance 
raises numerous questions about the manipulation 
and solutions for complex physiological abilities, 
such as fatigue and endurance. A promising 
concept of such drugs requires further studies 
into molecular regulatory role of PPAR* in the 
human muscle physiology to ensure their 
effective and safe use. 
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ULOGA PPAR-* U DETERMINACIJI MIŠIĆNIH VLAKANA U ODGOVORU 
NA VEŽBANJE 
 
Biljana Vitošević, Goran Ranković i Tatjana Popović-Ilić 
 
 
  Naporno vežbanje može indukovati promenu tipa mišićnog vlakna od tipa II 
glikolitičkog ka tipu I oksidativnom mišićnom vlaknu. Tačan molekularni mehanizam još 
uvek nije jasan, ali nuklearni receptor PPAR-* (peroxisome proliferator-activated 
receptor delta) i koaktivator PGC-1-α (peroxisome proliferator-activated receptor-gama 
co-activator-1α) ključni su faktori koji su odgovorni za povećanu mitohondrijalnu 
biogenezu i povećanje oksidativnog kapaciteta mišićnog vlakna, određujući na taj način 
fenotip mišića. Rad istražuje moguće mehanizme regulacije i uloge PPAR-delta u 
skeletnim mišićima i determinaciji tipa mišićnog vlakna u cilju pronalaženja rešenja za 
kompleksne  fiziološke sposobnosti kao što su zamor i izdržljivost.. Acta Medica 
Medianae 2011;50(2):57-62. 
 
Ključne reči: nuklearni receptor, tip mišićnog vlakna, vežbanje 